Biotech News

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences (PLSE)Pulse Biosciences2026-05-12 11:00 ESTCompany update

HAYWARD, Calif. --(BUSINESS WIRE)--May 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette,

Open original release

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

PLSEPulse Biosciences2026-05-27 20:05 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Stock data

Close: 32.79 USD
Market cap: 1.68B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Related news

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulse Biosciences

Recent company news

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026